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Noninfectious lung injury and acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell
transplantation (allo-HCT) are associated with signiﬁcant morbidity and mortality. Azithromycin is widely
used in allogeneic HCT recipients for pulmonary chronic GVHD, although current data appear controversial.
We induced GVHD and noninfectious lung injury in lethally irradiated B6D2F1 mice by transplanting bone
marrow and splenic T cells from allogeneic C57BL/6 mice. Experimental groups were treated with oral azi-
thromycin starting on day 14 until the end of week 6 or week 14 after transplantation. Azithromycin treat-
ment resulted in improved survival and decreased lung injury; the latter characterized by improved
pulmonary function, reduced peribronchial and perivascular inﬂammatory cell inﬁltrates along with
diminished collagen deposition, and a decrease in lung cytokine and chemokine expression. Azithromycin
also improved intestinal GVHD but did not affect liver GVHD at week 6 early after transplantation. At week 14,
azithromycin decreased liver GVHD but had no effect on intestinal GVHD. In vitro, allogeneic antigen-
presenting cell (APC)e dependent T cell proliferation and cytokine production were suppressed by azi-
thromycin and inversely correlated with relative regulatory T cell (Treg) expansion, whereas no effect was
seen when T cell proliferation occurred APC independently through CD3/CD28-stimulation. Further, azi-
thromycin reduced alloreactive T cell expansion but increased Treg expansion in vivo with corresponding
downregulation of MHC II on CD11cþ dendritic cells. These results demonstrate that preventive adminis-
tration of azithromycin can reduce the severity of acute GVHD and noninfectious lung injury after allo-HCT,
supporting further investigation in clinical trials.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Noninfectious lung injury and acute graft-versus-host
disease (GVHD) are major causes of morbidity and mortal-
ity after allogeneic hematopoietic cell transplantation
(allo-HCT). In 2011, the American Thoracic Society issued a
consensus statement on noninfectious lung injuryedgments on page 37.
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ty for Blood and Marrow Transplantation.summarized under the term Idiopathic Pneumonia Syndrome,
encompassing various clinical forms, which differ based on
the time of onset, course of disease, and treatment response
[1]. Variousmodels of rodents have been established to study
noninfectious lung injury after allo-HCT, and 2 major histo-
pathologic features similar to that seen in patients receiving
allo-HCT are commonly observed across models: peribron-
chial and perivascular lymphocytic inﬁltration and acute
pneumonitis of the alveolar spaces and the interstitium [1,2].
Although the exact pathophysiology is not completely un-
derstood, donor CD4þ T cells activated by antigen presenting
cells (APCs) [3-5] and shifting towards Th1 or Th17 pheno-
type [6,7], cytotoxic CD8þ T cells [8], and macrophages [5]
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such as TNF-a, IL-1b, IFN-g, and CCL2, CCL5, CXCL9-11, and
CXCL1 [9-11], respectively may also be contributive to the
disease process. Acute GVHD itself, sharing similar patho-
physiological characteristics, may be a predisposing and
driving factor of disease development.
Azithromycin is a macrolide antibiotic with established
anti-inﬂammatory properties and favorable toxicity proﬁle,
which attains very high and durable lung concentrations
[12]. Azithromycin treatment has been found to decrease
pulmonary exacerbations and improve lung function in pa-
tients with cystic ﬁbrosis (CF) [13,14], chronic obstructive
pulmonary disease, and non-CF bronchiectasis [15,16]. Azi-
thromycin has also been shown to be beneﬁcial in lung
transplantation for the prevention and treatment of chronic
allograft rejection [17,18]. Accordingly, azithromycin has
been studied in the setting of allo-HCT to treat bronchiolitis
obliterans syndrome (BOS), but studies were limited by small
patient numbers and demonstrated conﬂicting evidence of
therapeutic efﬁcacy [19,20]. In none of these studies, azi-
thromycin was given prophylactically with the intention to
prevent lung injury.
In this study, we use a well-established mouse model of
noninfectious lung injury after allo-HCT to determine
whether azithromycin started early and given over a pro-
longed time period is beneﬁcial in preventing pulmonary
damage, thereby improving pulmonary function and overall
outcome.
MATERIALS AND METHODS
Animal experiments were done at 3 different institutions: early GVHD
and pulmonary function testing experiments were done at the University of
Regensburg Medical Center (UKR), Regensburg, Germany, and the splenic T
cell expansion study was done at the University of Utah (UofU), Salt Lake
City, Utah. All other data presented are from experiments performed at
Louisiana State University Health Sciences Center Shreveport (LSUHSC-S),
Louisiana. All experiments were done with the approval of the local insti-
tutional animal committees.
Induction of GVHD and lung Injury
Female B6D2F1 (H-2bxd) and C57BL/6 (H-2b) mice were purchased from
the Jackson Laboratory (Bar Harbor, ME) or Charles River Laboratories
(Sulzbach, Germany) and acclimatized in the respective animal facility for at
least 1 week before starting the experiments. Animals were between 10 and
20 weeks old at the time of HCT or when used for in vitro studies.
Mice underwent bone marrow transplantation according to standard
protocol as previously described [9,21]. B6D2F1 mice were conditioned
using total body irradiation. Irradiation was done using either a linear
accelerator, 150 cGy/minute (UKR) or using a Cesium source irradiator
(LSUHSC-S and UofU), at a total dose of 12 Gy. Radiation was delivered in 2
fractions, 3 hours apart to reduce gastrointestinal toxicity. Animals then
received a cell mixture of 4 to 5  106 bone marrow cells and 6  106
splenocytes from either syngeneic B6D2F1 or allogeneic C57BL/6 donors via
tail vein injection. Mice were housed in sterilized microisolator cages and
received autoclaved (UKR) or normal (LSUHSC-S and UofU) chow and
autoclaved water for the ﬁrst 2 weeks.
At day 14 after transplantation, syngeneic and allogeneic recipients
were equally stratiﬁed based on weight loss into 2 subgroups: 1 group
received autoclaved water only whereas the other group received auto-
claved water supplemented with azithromycin dihydrate (Pﬁzer, Germany)
at a concentration of 1 mg/mL from day þ14 until day þ17 and .5 mg/mL
from day þ18 until end of week þ14 (UKR). At LSUHSC-S and UofU, azi-
thromycin (Sagent Pharmaceuticals, Schaumburg, IL) dosing was increased
to 3mg/mL to attain a dose of 450 to 600mg/kg/day to optimize study set up
[22]. Survival was monitored daily and GVHD clinical scores were assessed
weekly using 5 clinical parameters: weight loss, posture, mobility, fur
texture, and skin integrity, as previously described [2]. Animals were
sacriﬁced for analysis at end of week þ6 and þ14.
Histopathology
Lung injury was assessed by examination of lung histopathology. He-
matoxylin and eosinestained lung sections were independently evaluatedby the pathologist for the severity of periluminal inﬁltrates (around airways
and vessels) or parenchymal pneumonitis (involving the alveoli or inter-
stitium), using a previously described semiquantitative scoring system [2].
Final scores for periluminal and parenchymal inﬁltrates were obtained by
multiplication of the respective severity and extent. Liver and gut pathology
were also assessed by hematoxylin and eosin staining of the tissues and
independently evaluated by the pathologist, using previously described
scoring systems [23,24]. Trichrome staining for collagen (NovaUltra Masson
Trichrome Stain kit, IW-3006, IHC World, Woodstock, MD) was performed
as per manufacturer’s protocol. For immunostaining, 4 mm of organ slices
were dewaxed and rehydrated, followed by antigen unmasking using citrate
buffer pH 7.2 and microwave at 300W for 30 minutes. Next, peroxidase
blocking solution (S2023, Dako) was added for 5 minutes to quench
endogenous peroxidase activity. CD3þ cells were then detected by rabbit IgG
anti-mouse CD3 antibody (NeoMarkers, RM-9107-S [Thermo Fisher Scien-
tiﬁc GMBH, Dreieich, Germany]) in 1:50 dilution in antibody diluent (S2022,
Dako). Simple Stain Mouse MAX PO anti rabbit (414141F, Histoﬁne, NICHIREI
BIOSCIENCES INC, Tokyo, Japan) was used as the secondary antibody, visu-
alization using DAB (K3467, Dako) and counterstained using hematoxylin.
CD3þ staining was scored as cells per high power ﬁeld.
Bronchoalveolar Lavage
Bronchoalveolar lavage (BAL) and cell surface phenotyping were
performed as previously described and cells were analyzed by ﬂow
cytometry [2].
Pulmonary Function Testing
Assessment of pulmonary function was performed using a Buxco lung
function analysis system (Buxco Electronics, Troy, NY) consisting of a pul-
monary function test/forced maneuvers analyzer (SFT3840, Buxco) plus
pressure panel for mouse maneuvers (AUT6100, Buxco), and an anes-
thetized mouseepulmonary function test (PFT) plethysmograph (PLY3112,
Buxco) as previously described [25]. Data acquisition and analysis were done
using BioSystem XA software (SFT3850).
Tissue Cytokine and Chemokine Expression
At time of analysis, tissues were harvested and snap frozen. Supernatant
of homogenized tissue was obtained as described before [26]. Total protein
concentration in the supernatant was determined using Coomassie Bradford
protein assay (Thermo Scientiﬁc, Rockford, IL) to allow for cytokine and
chemokine concentration normalization to picograms per milligram of total
protein.
Cytokines and chemokines, such as TNF-a, IL-1b, CXCL1, CXCL9, CXCL10,
IL-15, CCL5, CCL3, and others were assayed by Millipore’s MILLIPLEX MAG
Mouse Cytokine/Chemokine kit (Billerica, MA) using Luminex xMAP tech-
nology according to manufacturer’s protocol. Cytokine/chemokine analysis
was also performed on tissues using ELISA for CXCL9, IFN-g,TNF-a, CCL2,
CXCL1, MIP-2, IL-6, and CXCL10 (Duoset, R&D Systems GmbH, Germany).
T cell Activation and Proliferation Assays
Mixed lymphocytic reaction (MLR) was done using irradiated (40 Gy)
BALB/c or B6D2F1splenocytes (8  105 cells per well) as stimulators. C57BL/
6 effector T cells were puriﬁed from splenocytes using MACS CD90$2 beads
and QuadroMACS system using LS columns (Miltenyi Biotec, Auburn, CA)
according to manufacturer’s protocol and cocultured in complete RPMI
medium in 2:1 stimulator to effector ratio at 4  105 cells per well in a 96-
well ﬂat bottom plate. CD3/CD28 Tcell activation assaywas performed using
C57BL/6 splenocytes at a concentration of 2  105 cells per well in complete
RPMI using antiCD3ε (Clone 145-2C11) and anti-CD28 (Clone 37$51, eBio-
science, San Jose, CA) antibody stimulation as per manufacturer’s protocol.
Cultures were incubated at 37C and 5% CO2, pulsed at 72 hours with 3H
thymidine (1 mCi) for MLR and at 48 hours for CD3/CD28 T cell activation
assay and harvested 24 hours later using PHD cell harvester (Brandel, MD).
Proliferation was quantiﬁed by using Wallac 1409 liquid scintillation
counter. Azithromycinwas added to respective groups at the concentrations
5 mg/mL, 10 mg/mL, and 20 mg/mL versus controls for the duration of the
assay. Average counts per minute were obtained from triplicates, and ex-
periments were done in duplicates. Supernatants were obtained before the
addition of 3H thymidine and stored at 80 C for cytokine analysis.
MLR and CD3/CD28 T cell activation assay supernatant were analyzed
for IFN-g, TNF-a, IL-10, IL-17, IL-2, IL-4, and IL-6 cytokine levels using
Cytometric Bead Array Mouse Th1/Th2/Th17 Cytokine Kit (BD Biosciences
Pharmingen, San Diego, CA) per manufacturer’s protocol.
T cell Migration Assay
Migration assay was performed using murine recombinant CXCL9
(DevaTal Inc., Trenton, NJ) as chemotactic stimulant at 100 nM/well using a
24-well transwell migration plate. Puriﬁed T cells at 5  105 cells per well
Figure 1. Survival at week þ6 and week þ14 after allo-HCT. Animals underwent transplantation as described in Materials and Methods. (A) Survival at week þ6 after
HCT. Azithromycin was used at 1 mg/mL for the ﬁrst 3 days starting on day þ14 and then at .5 mg/mL until day 42. (syngeneic control: n ¼ 5; allogeneic control:
n ¼ 10; azithromycin-treated allogeneic: n ¼ 8) Survival by Wilcoxon test. (B) Clinical GVHD score at week þ6 after HCT as described in Materials and Methods. (C)
Survival at week þ14 after HCT (syngeneic control: n ¼ 8; allogeneic control: n ¼ 17; azithromycin-treated allogeneic: n ¼ 15). Azithromycinwas used at 1 mg/mL for
the ﬁrst 3 days starting on day þ14 and then at .5 mg/mL until day þ98. (D) Survival at week þ14 (syngeneic control: n ¼ 5; syngeneic azithromycin-treated group:
n ¼ 4; allogeneic control: n ¼ 13; azithromycin-treated allogeneic group: n ¼ 14; survival by Wilcoxon test). Azithromycin was used at 3 mg/mL starting on day þ14
until day þ100.
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concentrations of 20 mg/mL and 50 mg/mL versus PBS control were used as
previously described [10].Flow Cytometry
Cells from BAL or MLR were phenotyped for CD3þ, CD4þ, CD8þ, and
Foxp3 expression. Cells from BAL or MLR were washed with PBS containing
4% FBS and incubated with FcR-block antimouse CD16/CD32 (Clone:93,
eBioscience, San Diego, CA) for 15 minutes at 4C. Following a washing step,
cells were incubated in a predetermined optimized concentration of anti-
bodies in a total volume of 100 mL. For intracellular staining for FoxP3, ﬁx-
ation and permeabilization were done as per protocol using the ﬁxation/
permeabilization concentrate and diluent (eBioscience). The following
antibody clones were used: CD3-FITC (17A2), CD4-APC (RM4-5), CD8a-
PerCP (53-6.7) CD11c (N418) MHCII (M5/114.15.2), CD80 (16-10A1), CD86
(GL-1) (all obtained from Biolegend, San Diego, CA) and FoxP3 PE (FJK-16s)
(eBioscience). CD8-FITC, Ly6c-FITC and CD4-PE (BD Pharmingen) were used
for the experiments at UKR. Cells were analyzed on BD LSR II, BD FACS Canto
or BD FACSCalibur (BD Biosciences). Flow cytometry data were analyzed
using FlowJo software (Tree Star, Ashland, OR).Splenic T cell Proliferation
Transplantation was performed as described above. In the day þ7 ex-
periments, the treatment group received azithromycin at 3 mg/mL for
2 weeks before and continued for 1 week after transplantation until analysis
at dayþ7. For the dayþ56 experiment, azithromycin (3 mg/mL) was started
at day þ14 after transplantation and continued until day þ56, the day of
analysis. Total spleen count was calculated and CD4þ, CD8þ T cells, and
FoxP3þ CD4þ T cells were quantiﬁed by using ﬂow cytometry as described
above (% positive cells  total spleen count). CD11c was used to identify
dendritic cells and the expression of MHC class II; CD86 and CD80 were
quantiﬁed using median ﬂuorescence intensity.Statistical Considerations
All values are expressed as mean  standard error of mean (SEM). Sta-
tistical comparisons between groups were made using either students T test
or 1-way ANOVA with Bonferroni comparison between groups, and the
Wilcoxon rank test was used for analyzing survival data. Signiﬁcance was
deﬁned as P < .05.RESULTS
Acute GVHD and Lung Injury are Reduced in
Azithromycin-treated Animals after Allogeneic HCT
Animals underwent transplantation and were treated
with azithromycin (1 mg/mL) versus control starting at
day þ14, as described above, and analyzed at day þ42. All
syngeneic and azithromycin-treated allogeneic recipients
survived, but only 50% of allogeneic controls were alive at
time of analysis (P ¼ .02) (Figure 1A). This survival beneﬁt
was associated with less clinical GVHD (Figure 1B). We next
assessed the effects of azithromycin treatment at a later time
point (14 weeks after transplantation) to determine whether
prolonged azithromycin is efﬁcacious to prevent disease
progression. All syngeneic animals, 29% of allogeneic control
animals, and 53% of allogeneic azithromycin-treated animals
were alive for the duration of the experiment (Figure 1C). In
spite of signiﬁcant changes in pulmonary function (discussed
below) yet only mild improvement in survival, we next
treated animals with azithromycin at a higher concentration
of 3 mg/mL to optimize drug efﬁcacy. Survival at week þ14
was signiﬁcantly higher in the azithromycin allogeneic group
compared with the control group (85.7% versus 53.8%;
P ¼ .04) (Figure 1D) and all syngeneic recipients (control and
treated group) survived. This experiment was performed at a
different institution, with irradiation given from a different
source, and animals kept in different facility, as described in
Material and Methods, possibly explaining the difference in
overall survival of allogeneic controls compared with previ-
ous experiments.
At week þ6 after HCT, BAL ﬂuid cellularity showed a
signiﬁcant increase in CD4þ and CD8þ T cells in allogeneic
recipients compared with syngeneic recipients without a
statistically signiﬁcant difference between allogeneic
azithromycin-treated animals and allogeneic controls.
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statistically differ from syngeneic controls (Figure 2AeC); in
addition, pulmonary function tests showed no signiﬁcant
differences between syngeneic and allogeneic groups
(Figure 2DeF). As reported in prior studies using this murine
allo-HCT model, histopathologic changes indicative of
noninfectious lung injury [25] were evident in the lungs of
allogeneic control-treated animals and signiﬁcantly reduced
in allogeneic recipients receiving azithromycin (Figure 2G).
This was associated with less gut GVHD in the azithromycin-
treated animals (Figure 2H) when compared with allogeneic
controls, whereas no difference in liver pathology was found
(Figure 2I).
At week þ14 after HCT, BAL ﬂuid cellularity revealed a
signiﬁcant decrease in CD4þ T cells in allogeneic azi-
thromycin recipients compared with allogeneic controls, as
well as a not statistically signiﬁcant decrease in CD8þ T cells
(Figure 2J,K). Lung function was assessed in surviving ani-
mals. Forced expiratory volume 50, lung compliance, and
forced vital capacity were signiﬁcantly better in the
azithromycin-treated allogeneic group compared with theFigure 2. Histopathology and pulmonary function at week þ6 and week þ14 after H
(A-C) Bronchoalveolar lavage (BAL) cell counts, CD4þ T cells, CD8þ T cells, and neutrop
week þ6 after HCT: FEV50, FVC, and compliance. (G-I) Pathology of the lung, gut, and li
Materials and Methods. (syngeneic control: n ¼ 5; allogeneic control: n ¼ 5; azithrom
cells by ﬂow cytometry at week þ14 after HCT. (L-N) Pulmonary function test at we
Trichrome (100x) in allogeneic control and allogeneic azithromycin-treated at week þ
semiquantitative scoring system as described in Materials and Method. (R) CD3þ ce
Pathology of the gut and liver by H&E staining at week þ14 after HCT using scoring s
(syn control: n ¼ 5; syn azithromycin: n ¼ 4; allogeneic control: n ¼ 7; allogeneic azith
magniﬁcations and for trichrome stain Nikon EclipseE400 microscope at 100 x magnallogeneic controls and similar to the syngeneic group
(Figure 2LeN). Lung injury was predominantly periluminal
with no difference in the parenchymal injury between
groups. The periluminal lung injury, consisting largely of
CD3þ T cells and collagen deposition, was decreased in the
azithromycin-treated allogeneic group compared with allo-
geneic controls (Figure 2OeR). Along with a reduction in
lung injury, there was a signiﬁcant reduction in hepatic
GVHD changes with a decrease in lymphocytic inﬁltration of
the bile ducts and diminished portal duct expansion sec-
ondary to inﬂammation. There was no difference in gut
histopathology observed between groups (Figure 2S,T).
In line with the observed effects on histopathology at
week þ6 in the lung, increased levels of CXCL1, IFN-g, and
CXCL9 were observed in allogeneic controls compared with
the syngeneic animals, and their expression was decreased
in allogeneic recipients treated with azithromycin
(Figure 3AeD). A signiﬁcant difference in inﬂammatory
cytokine and chemokine levels in the gut between the syn-
geneic group and the allogeneic controls was observed for
CCL2, IFN-g, CXCL9, and TNF-a. Azithromycin-treatedCT. Animals underwent transplantation as described in Materials and Methods
hils by ﬂow cytometry at week þ6 after HCT. (D-F) Pulmonary function test at
ver by H&E staining at week þ6 after HCT using scoring systems as described in
ycin-treated allogeneic: n ¼ 8). (J,K) BAL cell counts CD4þ T cells and CD8þ T
ek þ14 after HCT: FEV50, FVC, and compliance. (O) H/E, CD3þ IHC (400x) and
14 after HCT. (P,Q) Lung pathology at week þ14 by H&E staining scored using a
ll quantiﬁcation in the lung as cells per high power ﬁeld at week þ14. (S,T)
ystems as described in Materials and Methods. Results shown as mean  SEM
romycin: n ¼ 11). For H/E and CD3þ IHC, Zeiss Axioskop 40 microscope at 400 x
iﬁcation was used.
Figure 3. Tissue cytokine levels at week þ6 and week þ14 after allo-HCT. Animals underwent transplantation as described in Materials and Methods. (A-D) Cytokine
concentration in the lung analyzed in the lung supernatant by ELISA at week þ6 after HCT as described in Materials and Methods: IFN-g, CXCL1, MIP2, and CXCL9
respectively in pg/mg total protein. (E-H) Cytokine concentration in the gut by ELISA at weekþ6 after HCT: IFN-g, CCL-2, CXCL9, and TNF-a respectively in pg/mg total
protein. (syngeneic control: n ¼ 5; allogeneic control: n ¼ 5; azithromycin-treated allogeneic: n ¼ 8). Results shown as mean  SEM. (I-P) Cytokine concentration in
the lung at week þ14 analyzed in the lung supernatant using Luminex technology as described in Materials and Methods: CXCL9, CXCL10, CCL5, IL-1b, IL-15, TNF-a,
CCL3, and CXCL1 respectively in pg/mg total lung protein. Results shown as mean  SEM (syngeneic control: n ¼ 4; azithromycin-treated syngeneic: n ¼ 3; allogeneic
control: n ¼ 4; azithromycin-treated allogeneic n ¼ 6).
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IFN-g, but there was no difference in the other cytokines
when compared with allogeneic controls (Figure 3EeH). No
differences between syngeneic and allogeneic recipients
were seen for CXCL1, MIP-2, IL-6, and CXCL10 in the gut and
for MIP-2, IL-6,TNF-a, and CCL2 in lung, and there was no
difference in hepatic expression of any of the tested inﬂam-
matory mediators between groups at this time point (data
not shown).
At week þ14 after HCT, azithromycin-treated allogeneic
recipients demonstrated signiﬁcant suppression of CXCL9,
CCL5, IL-1b, IL-15, and TNF-a in the lungs compared with the
allogeneic controls and a nonsigniﬁcant decrease was seen
for CXCL10 (Figure 3IeN). CCL3 and CXCL1 levels were
elevated in both allogeneic groups when compared with the
syngeneic recipients, but they were not altered by azi-
thromycin treatment (Figure 3O,P). There was no difference
in cytokine expression in the liver between syngeneic and
allogeneic groups (data not shown).Azithromycin Decreases T cell proliferation in Response
to Alloantigen Presented by APCs through the Induction
of Regulatory T cells
We then testedwhether azithromycin alters alloreactive T
cell responses when alloantigens are presented by APCs,
thereby modulating the development of GVHD. Signiﬁcant
suppression of responder C57BL/6 T cell proliferation to
B6D2F1 or BALB/c splenocytes as stimulators was observed
as the concentration of azithromycin was increased
(Figure 4A,B). Decreased proliferation was associated with
reduced levels of cytokines (IFN-g, TNF-a, IL-6, IL-10, IL-17) in
the MLR supernatant, whereas no differences were seen for
IL-2; IL-4 was undetectable (Table 1). In contrast, when T cell
activation occurred directly through anti-CD3/CD28 stimu-
lation and in the absence of alloreactive APCs, no differences
in T cell proliferation (Figure 4C) or cytokine expressionwere
seen (Table 1).
Azithromycin-related decrease of T cell proliferation in
MLRs was associated with an increase in the percentage of
Figure 4. Azithromycin decreases T cell proliferation in response to alloantigen presented by APCs through the induction of regulatory T cells. Mixed lymphocytic
reaction (MLR) using C57BL/6 T cells as responders and irradiated (A) B6D2F1 or (B) BALB/c splenocytes as stimulators at varying concentrations of azithromycin. (C)
Anti-CD3/CD28 induced T cell proliferation using C57BL/6 as responders at varying concentrations of azithromycin. (D-E) Percentage of regulatory CD4þ Foxp3þ T
cells (Tregs) of all CD4þ T cells was quantiﬁed by ﬂow cytometry in (D) MLR and (E) Anti-CD3/CD28 activation. (F) In vitro T cell migration assay using CXCL9 at
different concentrations of azithromycin compared to control as described in Material and Methods. Results shown as mean  SEM; all experiments done in
triplicates.
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(Figure 4D), whereas when using anti-CD3/CD28 activation,
no difference in Treg percentage was found (Figure 4E),
suggesting that azithromycin induces the expansion of CD4þ
FOXP3þ Tregs only in the presence of alloreactive APCs.Table 1
Inﬂammatory Cytokine Expression in T Cell Proliferation
Cytokines in pg/mL Azithromycin (mg/mL)
0
MLR cpm 20053  1041
IFN-G 590.5  59.9
TNF 139.1  8.0
IL-2 27.0  0.6
IL-10 115.5  8.8
IL-17 24.7  0.9
IL-6 169.3  8.3
IL-4 .
CD3/CD28 cpm 54868  1873
IFN-G 9248  467
TNF 381.7  20.64
IL-2 735.3  87.64
IL-10 30.9  2.3
IL-17 37.68  8.3
IL-6 82.45  12.2
IL-4 .
Supernatants of T cell proliferation assays (MLR versus anti-CD3/CD28 stimulation)
IL-2, IL-10, IL-17, IL-6, IL-4 using cytometric bead array as described in Material
triplicates.
CPM indicates count per minute; ., below detection.
* P < .05.
y P < .01.
z P < .001.To test whether azithromycin directly alters themigratory
properties of T cells, we performed a T cell migration assay
using CXCL9 as the chemo attractant. The addition of azi-
thromycin in 2 different concentrations (20 mg/mL and 50 mg/
mL) did not affect the number of transwell migrated cells5 10 20
17497  1237 15340  1157* 12902  1317y
476.0  42.6 363.6  18.6y 218.7  19.2z
114.2  5.4* 115.4  5.6* 104.6  2.5y
23.4  1.2 23.4  0.2 25.2  1.0
99.1  14.4 98.9  4.3 65.0  6.8y
19.3  3.3 17.6  1.1 9.4  1.5z
139.6  16.3 120.7  11.7* 96.7  9.4y
. . .
51182  2071 51351  1447 51659  862
9860  626.5 8570  697.7 8994  557.6
382.1  11.71 366.5  18.27 371.9  19.73
630.9  21.86 675.4  40.2 709.9  40.1
29.5  3.6 36.58  6.9 44.01  7.6
38.61  5.4 27.01  4.2 35.58  6.0
79.63  5.1 85.22  6.0 75.23  15.3
. . .
with varying concentrations of azithromycin were analyzed for IFN-g, TNF-a,
s and Methods. Results shown are mean  SEM; all experiments done in
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direct effects on T cell migration in vitro.
Azithromycin Suppresses Alloreactive Splenic T cell
Proliferation in Vivo at Day þ7 and Day þ56 after HCT
and Induces Regulatory T cells
As the addition of azithromycin suppressed T cell prolif-
eration in vitro in an APC-dependent fashion, we next tested
if azithromycin is able to decrease alloreactive T cell prolif-
eration in vivo at 2 different time points after trans-
plantation: at day þ7 and day þ56. Splenic T cell expansion
was determined on day þ7 and day þ56 after bone marrow
transplantation. On day þ7, a signiﬁcant decrease in both
CD4þ and CD8þ splenic T cells was observed in the
azithromycin-treated group when compared with control-
treated animals (Figure 5A,B), and the proportion of
CD4þFoxp3þTregs was slightly although not signiﬁcantly
increased in the azithromycin-treated groupwhen compared
to allogeneic controls (Figure 5C). The suppression of splenic
T cell proliferation of CD4þ and CD8þ cells was still evident at
day þ56, although it was not statistically signiﬁcant
(Figure 5D,E), and a signiﬁcant induction of CD4þ Foxp3þ
Tregs in the azithromycin-treated group compared to the
allogeneic controls was observed (Figure 5F). These changes
were accompanied by a corresponding suppression of MHC
class II expression on the CD11cþ dendritic cells in the
azithromycin-treated group compared with the allogeneic
control group (Figure 5G). Therewas no signiﬁcant difference
in the expression of CD80þ or CD86þ on these dendritic cells
(data not shown).
DISCUSSION
Noninfectious pulmonary complications after allo-HCT
present a major cause for transplantation-related morbidity
and mortality and can present as both restrictive and
obstructive lung injury. Although azithromycin is commonly
used in patients with late-occurring obstructive lung injury
after allo-HCT, well-controlled data on its use in these pa-
tients are limited. Khalid et al. reported a small series of
patients with BOS after allo-HCT, in which treatment with
azithromycin resulted in stabilization of disease [20],
whereas 2 other groups did not show clear efﬁcacy in thisFigure 5. Azithromycin suppresses alloreactive splenic T cell proliferation in vivo at da
transplantation as described in Materials and Methods. (A,B) Splenic CD4þ T cell and
treated animals expressed as cells/spleen. (C) Percentage of regulatory CD4þ Foxp3
thromycin recipients (n ¼ 6 in both groups). (D,E) Splenic CD4þ T cell and CD8þ T
expressed as cells per spleen. (F) Percentage of regulatory CD4þ Foxp3þ T cells of total
(G) MHC class II expression on CD11cþ dendritic cells in the control and azithromycin
as mean  SEM.setting [19,27]. However, in both of these studies, azi-
thromycin was initiated for established BOS, and it remains
unanswered whether preemptive use of azithromycin early
after allo-HCT, because of its anti-inﬂammatory and bacte-
riostatic effects, would affect acute GVHD and early lung
injury, potentially altering the overall clinical course of lung
injury after allogeneic HCT. Animal studies on the use of
azithromycin in allo-HCT are also limited. Recently, using a
murine HCT model, Iwamoto et al. showed that azi-
thromycin, when given very early, can result in improved
survival and decreased early tissue injury of the liver and
intestine after allo-HCT [28].
Using a well-established murine model for lung injury
after allo-HCT [29], we demonstrated that preventive early
treatment with azithromycin given over a prolonged period
of time decreases lung injury and improves overall survival.
Histological hallmarks in murine models of lung disease
after allogeneic HCT include lymphocytic peribronchiolitis,
interstitial pneumonitis, ﬁbrosis, and BOS [2,5,29-32]. In
our model, lung injury after allo-HCT has been classiﬁed
more as a interstitial pneumonitis form of acute lung injury,
but our group and others have shown that this lung injury
in mice worsens over time, with inﬂammatory changes
progressively shifting toward peribronchial and peri-
vascular structures, along with increasing pulmonary
obstruction [25,29]. We now show that the preemptive use
of azithromycin, initiated early at 14 days after trans-
plantation, before major signiﬁcant structural changes have
occurred, results in a decrease in lung pathology and lung
function decline when assessed at 6 weeks and 3 months
later. Consistent with a similar study by Cohen et al. [29],
we did not observe bronchiolitis obliterans in this model.
Periluminal inﬁltrates at 14 weeks showed a higher
percentage of CD3þ cells in control-treated versus
azithromycin-treated animals. In the BAL of allogeneic
controls, a predominance of CD4þ T cells compared with the
CD8þ T cells was found, supporting previous reports that
CD4þ T cells may be more involved in chronic lung injury,
whereas CD8þ T cells are rather increased early [10,29].
Decreased lung injury in azithromycin-treated animals was
associated with a signiﬁcant reduction in BAL CD4þ and, to
a lesser degree, CD8þ T cells, as well as in decreased CD3þy þ7 and day þ56 after HCT and induces regulatory T cells. Animals underwent
CD8þ T cell proliferation in allogeneic controls and allogeneic azithromycin-
þ T cells of total cells in the spleen of allogeneic controls and allogeneic azi-
cell proliferation in the allogeneic controls and azithromycin-treated animals
cells in the spleen of allogeneic controls and allogeneic azithromycin recipients
-treated recipients (control n ¼ 9, azithromycin-treated n ¼ 10). Results shown
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ﬁbrosis.
In addition to its bacteriostatic effects, azithromycin has
known anti-inﬂammatory properties. T cell recruitment to
the lungs partially depends on the expression of CXCL9 and
CXCL10 [11], with donor T cellederived CCL5 being an
amplifying factor [10]. It is likely that azithromycin exerted
direct anti-inﬂammatory properties, suppressing pulmonary
cytokine and chemokine expression and, thereby, decreased
T cell inﬁltration and lung pathology in this model. Early in
the post-transplantation period at week 6, azithromycin-
treated animals demonstrated suppressed pulmonary IFN-g
and CXCL9 expression, associated with less inﬂammation
and improved survival. In addition, at this time, diminished
gut injury was observed along with a reduction of intestinal
CCL2, IFN-g, and CXCL9, in keeping with an IFN-gemediated
Th1 response during acute GVHD. At a later time point at
week 14, when IFN-g expression is known to be not elevated
in the lung in this model [29], interestingly, the suppressive
effects of azithromycin treatment on CXCL9 along with
CXCL10 were sustained. Although these chemokines are
classically considered “interferon gamma inducible,” other
proinﬂammatory cytokines likely contribute to their
expression as well [33]. This persistence of decreased
expression could be a compound result of local suppression
of inﬂammation and decreased number of inﬁltrating allor-
eactive T cells. IL-15 has been shown to contribute to GVHD
severity [34], most likely through the expansion of CD8þ
memory T cells and maturation of dendritic cells [35], and in
our study azithromycin treatment resulted in decreased IL-
15 levels in the lungs after allo-HCT, suggesting that IL-15
suppression possibly contributes to reduction in pulmonary
T cell inﬁltration and lung injury. Further supportive of the
anti-inﬂammatory effects of azithromycin in ourmodel, TNF-
a and IL-1b, cytokines associated with increased tissue
damage and lung injury [36], were signiﬁcantly reduced in
the lungs of azithromycin-treated allo recipients and corre-
latedwith less pathology and improved survival in this group
at week 14. CXCL1, which is known to be suppressed by
azithromycin during pulmonary inﬂammation [37], was also
decreased both early and late after allo-HCT in our model, yet
neutrophils do not seem to play a critical role in this model of
lung injury (unpublished data).
Interestingly, we could demonstrate that azithromycin
can suppress T cell expansion and T cell cytokine production
in vitro and that this was only seen in the presence of allo-
antigen presenting cells, but not when T cell responses were
induced speciﬁcally via CD3/CD28 activation. Furthermore,
decreased T cell activationwas associated with the induction
of Tregs both in vitro and in vivo. Consistently, azithromycin-
treated bone marrowederived dendritic cells, when used
in vitro as stimulators, are known to decrease T cell prolif-
eration [38]. In our study, we were able to show in vivo
suppression of MHC class II expression on dendritic cells in
azithromycin-treated animals similar to the reported in vitro
suppression of MHC class II expression on CD11cþ dendritic
cells as reported by Iwamoto et al. [38]. Our in vivo ﬁndings
further demonstrate a corresponding increase in the Treg
expansion. This was not observed when T cell activation
occurred through T cell receptor/costimulatory molecule
antibody stimulation in the actual absence of APCs. This
suggests that the observed effects of azithromycin on allor-
eactive T cell proliferation seem not related to direct effects
on T cells, but rather are mediated through its actions on
APCs. Tregs have been shown to prevent the development ofbronchiolitis obliterans in lung transplant recipients [39,40].
Azithromycin achieves high drug concentrations in the lung
[12], and it is possible that in addition to its systemic effects,
sustained pulmonary induction of Tregs occurs during dis-
ease development.
Azithromycin is usually a well-tolerated antibiotic with
convenient dosing that attains high lung tissue concentra-
tions [12]. Despite recent concerns related to its arrhyth-
mogenic potential [41], with an increased cardiovascular risk
speciﬁcally for patients with high cardiovascular risk scores,
none of the studies on the use of azithromycin in lung
transplantation have shown increased azithromycin-
associated severe adverse effects [17]. Long-term use of azi-
thromycin in CF patients has shown an increased incidence
of infection with nontuberculous mycobacteria secondary to
its inhibitory effects on autophagy [42], and monitoring HCT
recipients, due to their immunocompromised state, for
nontuberculous mycobacteria infections may be beneﬁcial
when given azithromycin over a prolonged time period.
In summary, our study showed that azithromycin treat-
ment given prophylactically before or started early after
transplantation improved survival and decreased GVHD
severity and noninfectious lung injury in allo HCT recipients.
The beneﬁcial effects of azithromycin seemed multipronged,
involving the suppression of inﬂammation in the absence of
microbial infection, cytokine and chemokine-related modu-
lation of T cell migration, and inhibition of alloreactive pro-
liferative T cell responses through the induction of Tregs. Our
study supports the value of azithromycin in the prevention
and treatment of noninfectious lung injury after allo-HCT
under controlled experimental conditions in association
with possible beneﬁcial effects on acute GVHD.ACKNOWLEDGMENTS
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